Teva should face trimmed US antitrust claims from Myan over Copaxone, special master recommends
MLex Summary: Teva Pharmaceuticals should be denied dismissal as to most allegations brought by Mylan in a US antitrust case over generic Copaxone, a special master recommended. Special Master Faith S....To view the full article, register now.
Already a subscriber? Click here to view full article